Qvents

Qvents

Discussion forum for Pharma Quality events, Regulatory Actions

Warning letters, 483s, Recalls, Import Alerts, Audit observations

Jubilant USFDA 483 cites poor Chromatogr

USFDA 483 to Jubilant Roorkee cited inadequate review of unexplained discrepancies, aborting dissolution testing analysis for

Jubilant USFDA 483 – Lapses QC equipme

USFDA 483 for Jubilant Roorke cited inadequacies in investigation of equipment breakdowns, error messages, alarms.

Strides recall Prednisolone tablets for

Strides in July 2022 recalled from US market 1032 bottles of Prednisolone USP 20mg tablets for

USFDA Warning letter to Mylan on Handlin

USFDA Warning letter to Mylan in 2020 cited inadequacy of cleaning, cleaning procedures, risk assessment of

Warning letter /Mylan / MARCS-CMS 607508

USFDA Warning letter to Mylan in 2020 cited inadequate procedures to monitor and control recovered

Lapses in Process Validations: Torrent U

An USFDA 483 (2019) to Torrent cites deficient Process validation practices and procedures. The observations

Invalidation of OOS Results and Retestin

Torrent Indrad, India (FEI 3005029956) was issued USFDA form 483 following inspections by USFDA inspectors Lata Mathew, Jogy

Instrument Settings, Operator Training:

Following the USFDA inspection  during 8-16 April 2019 at Torrent, Indrad, India (FEI 3005029956) by

Deficient OOS Investigation and Handling

USFDA 483 Torrent Indrad facility in India (FEI 3005029956); inspection from 8 April 2019 to

Lack of Training and Awareness Across Ma

USFDA 483 to Lupin Pithampur unit cite Inadequacy of training and awareness across the management